{
  "Variants Include": [
    {
      "Gene": "SNCA",
      "variants": [
        {
          "HGVS": "NM_000179.4:c.2091G>A",
          "cDNA Change": {
            "transcript": "NM_000179.4",
            "ref": "G",
            "alt": "A",
            "position": "2091"
          },
          "Protein Change": {
            "ref": "G",
            "alt": "A",
            "position": "697"
          },
          "Description in input context": "This missense variant results in a substitution of Alanine for Threonine at position 697 of the SNCA protein."
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's Disease",
    "MONDO": "MONDO:0003821"
  },
  "Experiment Method": [
    {
      "Assay Method": "Immunofluorescence Microscopy",
      "Material used": {
        "Material Source": "Patient-derived fibroblasts",
        "Material Name": "Fibroblasts from Parkinson's Disease patients",
        "Description": "Fibroblasts were obtained from patients diagnosed with early-onset Parkinson's disease and cultured at 37°C in 5% CO2."
      },
      "Readout type": "Qualitative/Semi-Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000179.4:c.2091G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Increased intracellular aggregation and reduced protein clearance",
          "Result Description": "Immunofluorescence revealed a significant increase in α-synuclein aggregates and reduced lysosomal marker co-localization within fibroblasts carrying the SNCA missense variant, compared to control fibroblasts.  Aggregate size was also visibly increased."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Three independent fibroblast lines from separate patients carrying the SNCA variant were used in the analysis."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each condition (variant-carrying vs. control) was imaged three times per replicate fibroblast line."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Fibroblasts carrying a known pathogenic SNCA duplication were used as a positive control to demonstrate aggregation phenotypes."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Wild-type fibroblasts from healthy donors were used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "No",
        "Counts": "0"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "No",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "ANOVA followed by Tukey's post-hoc test was used to compare aggregate burden between conditions."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "α-synuclein aggregate area less than 200 µm² per cell.",
        "Source": "Custom - based on observations from healthy control fibroblasts."
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "α-synuclein aggregate area greater than 500 µm² per cell.",
        "Source": "Custom - based on observations from variant-carrying fibroblasts."
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}